We are live on ! Find out more
LPCN icon

Lipocine
LPCN

18 hedge funds and large institutions have $1.67M invested in Lipocine in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

137% more capital inflows, than outflows

Capital inflows: $61.7K | Capital outflows: $26.1K

0.2% more ownership

Funds ownership: 9.67% → 9.88% (+0.2%)

5% less funds holding

Funds holding: 19 → 18 (-1)

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
18
Holders Change
-1
Holders Change %
-5.26%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
5
Reduced
6
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Barclays
Barclays
United Kingdom
+$30.5K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$22.8K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$7.28K
4
UBS Group
UBS Group
Switzerland
+$896
5
Osaic Holdings
Osaic Holdings
Arizona
+$133

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$8.8K
2
Morgan Stanley
Morgan Stanley
New York
-$6.49K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$4.54K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$3.48K
5
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
-$1.83K

LPCN Hedge Fund Activity: Q2 2025 in Review

18 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q2 2025, worth a combined $1.67M — up 1.5% from $1.65M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of LPCN and 1 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 5 added.

The largest buyer was Barclays, opening a new position worth an estimated $30.5K. The largest seller was Renaissance Technologies, cutting an estimated $8.8K.

  • 18 institutional investors held Lipocine (LPCN) as of Q2 2025, down from 19 in Q1 2025.
  • Funds reported $1.67M of Lipocine stock for Q2 2025, up 1.5% quarter-over-quarter.
  • 1 fund opened new Lipocine positions in Q2 2025 and 2 closed out, a net change of -1 holder.
  • The largest Lipocine buyer in Q2 2025 was Barclays, an estimated $30.5K added.
  • The largest Lipocine seller in Q2 2025 was Renaissance Technologies, an estimated $8.8K sold.

Based on aggregated 13F filings for Q2 2025.